Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Intellia Therapeutics (NTLA) EBITDA (2016 - 2026)

Intellia Therapeutics has reported EBITDA over the past 12 years, most recently at -$97.5 million for Q1 2026.

  • Quarterly EBITDA rose 14.38% to -$97.5 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$395.9 million through Mar 2026, up 24.43% year-over-year, with the annual reading at -$412.3 million for FY2025, 20.46% up from the prior year.
  • EBITDA was -$97.5 million for Q1 2026 at Intellia Therapeutics, down from -$95.7 million in the prior quarter.
  • Over five years, EBITDA peaked at -$95.7 million in Q4 2025 and troughed at -$152.3 million in Q1 2022.
  • The 5-year median for EBITDA is -$113.0 million (2022), against an average of -$116.7 million.
  • Year-over-year, EBITDA tumbled 229.53% in 2022 and then skyrocketed 35.43% in 2023.
  • A 5-year view of EBITDA shows it stood at -$111.5 million in 2022, then dropped by 17.35% to -$130.8 million in 2023, then fell by 0.57% to -$131.6 million in 2024, then rose by 27.24% to -$95.7 million in 2025, then dropped by 1.84% to -$97.5 million in 2026.
  • Per Business Quant, the three most recent readings for NTLA's EBITDA are -$97.5 million (Q1 2026), -$95.7 million (Q4 2025), and -$101.0 million (Q3 2025).